UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 10-Q

 


 

(Mark One)

 

Quarterly report under Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Quarter Ended December 31, 2021

 

Transition report under Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from _______ to _______.

 

Commission file number: 333-256498

 

REST EZ, INC.

(Name of Registrant in Its Charter)

 

Wyoming

82-4268982

(State or Other Jurisdiction of Incorporation or

(I.R.S. Employer Identification No.)

Organization)

 

 

1398 W. Mason Hollow Dr.
Riverton, UT 84065

(Address of Principal Executive Offices)

 

(801) 300-2542
(Issuer’s Telephone Number, Including Area Code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol

Name of each exchange on which registered

None

None

None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.

 

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

As of February 8, 2022, there were 20,000,000 shares of the registrant’s common stock outstanding.

 

 

 

FORM 10-Q

 

TABLE OF CONTENTS

 

Note About Forward-Looking Statements

 

 

 

 

 

 

PART I

FINANCIAL INFORMATION

 

 

 

 

 

 

Item 1.

Financial Statements

 

4

 

 

 

 

 

Balance Sheets as of December 31, 2021 (Unaudited) and March 31, 2021

 

4

 

 

 

 

 

Statements of Operations for the three and nine months ended December 31, 2021 and 2020 (Unaudited)

 

5

 

 

 

 

 

Statements of Changes in Shareholders’ Equity (Deficit) for the three and nine months ended December 31, 2021 and 2020 (Unaudited)

 

6

 

 

 

 

 

Statements of Cash Flows for the nine months ended December 31, 2021 and 2020 (Unaudited)

 

7

 

 

 

 

 

Notes to Financial Statements (Unaudited)

 

8

 

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

12

 

 

 

 

Item 4.

Controls and Procedures

 

16

 

 

 

 

 

 

 

 

PART II

OTHER INFORMATION

 

 

 

 

 

 

Item 1.

Legal Proceedings

 

17

 

 

 

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

 

17

 

 

 

 

Item 3.

Defaults Upon Senior Securities

 

17

 

 

 

 

Item 4.

Mine Safety Disclosures

 

17

 

 

 

 

Item 5.

Other Information

 

17

 

 

 

 

Item 6.

Exhibits

 

17

 

 

 

 

 

Signatures

 

18

 

 

 

NOTE ABOUT FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, among other things, statements regarding plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements, which are other than statements of historical facts. Forward-looking statements may appear throughout this report, including without limitation, Item 2 “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Forward-looking statements generally can be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties, which could cause our actual results to differ materially from those reflected in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this report and in our Form S-1/A, and in particular, the risks discussed under the caption “Risk Factors” in Item 1A of this report and in in our Form S-1/A, and those discussed in other documents we file with the Securities and Exchange Commission (“SEC”). Important factors that in our view could cause material adverse effects on our financial condition and results of operations include, but are not limited to, risks associated with service demands and acceptance, our ability to expand, changes in healthcare practices, changes in technology, economic conditions, the impact of competition and pricing, government regulation and approvals, impacts and disruptions caused by the COVID-19 pandemic and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. We undertake no obligation to revise or publicly release the results of any revision to any forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

 

As used herein, the “Company,” “we,” “our,” and similar terms include Rest EZ, Inc. and its predecessors, unless the context indicates otherwise.

 

 

 

 

 

3

 

PART I FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

REST EZ, INC.

BALANCE SHEETS

 

   

 December 31,

   

 March 31,

 
   

2021

   

2021

 

ASSETS

 

 (unaudited)

         

Current assets

               

Cash and cash equivalents

  $ 83     $ 12,350  

Deposits

    405,000       80,150  

Inventory

    2,550       26,450  

Total Current Assets

    407,633       118,950  
                 

Total Assets

    407,633       118,950  
                 

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

               

Current liabilities

               

Deferred revenue

    -       -  

Due to related party

    115,136       133,061  

Total current liabilities

    115,136       133,061  
                 

Stockholders' equity (deficit)

               

Common stock, $0.001 par value, 100,000,000 shares authorized, 20,000,000 shares issued and outstanding as of December 31, 2021 and March 31, 2021

    20,000       20,000  

Additional paid-in capital

    108,922       21,307  

Retained earnings (Accumulated deficit)

    163,575       (55,418 )

Total stockholders' equity (deficit)

    292,497       (14,111 )
                 

Total liabilities and stockholders' equity (deficit)

  $ 407,633     $ 118,950  

 

The accompanying notes are an integral part of the unaudited financial statements.

 

4

 

REST EZ, INC.

STATEMENTS OF OPERATIONS

(UNAUDITED)

 

   

For the Three

   

For the Three

   

For the Nine

   

For the Nine

 
   

Months Ended

   

Months Ended

   

Months Ended

   

Months Ended

 
   

December 31,

   

December 31,

   

December 31,

   

December 31,

 
   

2021

   

2020

   

2021

   

2020

 
                                 

Revenue

  $ 345,000     $ -     $ 519,443     $ -  

Cost of goods sold

    165,000       -       269,050       -  

Gross profit

    180,000       -       250,393       -  
                                 

Operating expenses:

                               

General and administrative

    9,875       12,520       23,785       12,580  
                                 

Total operating expenses

    9,875       12,520       23,785       12,580  
                                 

Net Operating Income (loss)

    170,125       (12,520 )     226,608       (12,580 )
                                 

Other income (expense):

                               

Interest expense

    (2,303 )     (2,661 )     (7,615 )     (7,981 )

Total other expense

    (2,303 )     (2,661 )     (7,615 )     (7,981 )
                                 

Income (loss) before provision for income taxes

    167,822       (15,181 )     218,993       (20,561 )
                                 

Provision for income taxes

    -       -       -       -  
                                 

Net income (loss)

  $ 167,822     $ (15,181 )   $ 218,993     $ (20,561 )
                                 

Net income (loss) per share - basic

  $ 0.01     $ (0.00 )   $ 0.01     $ (0.00 )
                                 

Net income (loss) per share - diluted

  $ 0.01     $ (0.00 )   $ 0.01     $ (0.00 )
                                 

Weighted average shares outstanding - basic

    20,000,000       20,000,000       20,000,000       20,000,000  
                                 

Weighted average shares outstanding - diluted

    20,000,000       20,000,000       20,000,000       20,000,000  

 

The accompanying notes are an integral part of the unaudited financial statements.

 

5

 

REST EZ, INC.

STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (DEFICIT)

(UNAUDITED)

 

For the Three Months Ended December 31, 2021 and 2020

 

                                   

 Total

 
   

 Common Stock

   

 Additional

           

Stockholder's

 
                   

 Paid-In

   

Accumulated

   

 Equity

 
   

 Shares

   

 Amount

   

 Capital

   

 Deficit

   

 (Deficit)

 
                                         

 Balance, September 30, 2020

    20,000,000     $ 20,000     $ 15,985     $ (37,576

)

  $ (1,591

)

 Imputed interest on related party loan

    -       -       2,661       -       2,661  

 Net income for the three months ended December 31, 2020

    -       -       -       (15,181 )     (15,181 )

 Balance, December 31, 2020

    20,000,000     $ 20,000     $ 18,646     $ (52,757 )   $ (14,111 )
                                         

 Balance, September 30, 2021

    20,000,000     $ 20,000     $ 89,019     $ (4,247

)

  $ 104,772  

 Imputed interest on related party loan

    -       -       2,303       -       2,303  

 Proceeds from contributed capital

    -       -       17,600       -       17,600  

 Net income for the three months ended December 31, 2021

    -       -       -       167,822       167,822  

 Balance, December 31, 2021

    20,000,000     $ 20,000     $ 108,922     $ 163,575     $ 292,497  

 

For the Nine Months Ended December 31, 2021 and 2020

 

                                   

 Total

 
   

 Common Stock

   

 Additional

           

Stockholder's

 
                   

 Paid-In

   

 Accumulated

   

 Equity

 
   

 Shares

   

 Amount

   

 Capital

   

 Deficit

   

 (Deficit)

 
                                         

 Balance, March 31, 2020

    20,000,000     $ 20,000     $ 10,665     $ (32,196

)

  $ (1,531

)

 Imputed interest on related party loan

    -       -       7,981       -       7,981  

 Net loss for the nine months ended December 31, 2020

    -       -       -       (20,561

)

    (20,561

)

 Balance, December 31, 2020

    20,000,000     $ 20,000     $ 18,646     $ (52,757

)

  $ (14,111

)

                                         

 Balance, March 31, 2021

    20,000,000     $ 20,000     $ 21,307     $ (55,418

)

  $ (14,111

)

 Imputed interest on related party loan

    -       -       7,615       -       7,615  

 Proceeds from contributed capital

    -       -       80,000       -       80,000  

 Net income for the nine months ended December 31, 2021

    -       -       -       218,993       218,993  

 Balance, December 31, 2021

    20,000,000     $ 20,000     $ 108,922     $ 163,575     $ 292,497  

 

The accompanying notes are an integral part of the unaudited financial statements.

 

6

 

REST EZ, INC.

STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

   

For the Nine

   

For the Nine

 
   

Months Ended

   

Months Ended

 
   

December 31,

   

December 31,

 
   

2021

   

2020

 

CASH FLOWS FROM OPERATING ACTIVITIES

               

Net income (loss)

  $ 218,993     $ (20,561 )

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

               

Imputed interest on related party loan

    7,615       7,981  
                 

Changes in assets and liabilities:

               

Deposits

    (324,850 )     -  

Inventory

    23,900       -  

Bank overdraft

    -       (6 )

Deferred revenue

    -       105,000  

Due to related party

    (17,925 )     86  

Net cash provided by (used in) operating activities

    (92,267 )     92,500  
                 

CASH FLOWS FROM FINANCING ACTIVITIES

               

Proceeds from contributed capital

    80,000       -  

Net cash provided by financing activities

    80,000       -  
                 

Net Increase (Decrease) in cash and cash equivalents

    (12,267 )     92,500  
                 

Cash and cash equivalents at beginning of period

    12,350       -  
                 

Cash and cash equivalents at end of period

  $ 83     $ 92,500  
                 

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

               

Interest paid

  $ -     $ -  

Income taxes paid

  $ -     $ -  

 

The accompanying notes are an integral part of the unaudited financial statements.

 

7

 

REST EZ, INC.

NOTES TO UNAUDITED FINANCIAL STATEMENTS

December 31, 2021

 

Note 1. General Organization and Business

 

Rest EZ, Inc. (the “Company”) was incorporated on October 17, 2016. The Company has passed through all stages of development to full operations from incorporation, at the present time the company is currently in full Production and Distribution to wholesalers and retailers as well as online at www.RestEz.net. Rest EZ Inc. has commenced its major operations of having one product a liquid gel capsule named Rest EZ Sleep Aid Supplement, manufactured by an unaffiliated outside provider (Sport Energy) that manufactures liquid gels to various Companies, but has not distributed this product to anyone except Rest EZ Inc.

 

The Company’s year-end is March 31.

 

Note 2. Summary of Significant Accounting Policies

 

Basis of Presentation

 

The financial statements have been prepared in accordance with United States generally accepted accounting principles and reflect all adjustments which, in the opinion of management, are necessary for a fair presentation. All such adjustments are of a normal recurring nature. Interim results are not necessarily indicative of results for a full year. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s financial statements for the year ended March 31, 2021 contained in the Registration Statement on Form S-1, filed with the SEC on May 26, 2021.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

 

Fair Value of Financial Instruments

 

The Company’s balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period between the origination of these instruments and their expected realization.

 

FASB Accounting Standards Codification (ASC) 820 Fair Value Measurements and Disclosures (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

 

Level 1 -

Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

 

 

Level 2 -

Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

 

 

Level 3 -

Inputs that are both significant to the fair value measurement and unobservable.

 

The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash and accrued expenses reported on the balance sheet are estimated by management to approximate fair value primarily due to the short-term nature of the instruments. The Company had no items that required fair value measurement on a recurring basis.

 

8

 

Revenue Recognition

 

The Company recognizes revenue from product sales upon product delivery. All of our products are shipped through a third-party fulfillment center to the customer and the customer takes title to product and assumes risk and ownership of the product when it is delivered. Shipping charges to customers and sales taxes collectible from customers, if any, are included in revenues. Deferred revenue recorded on the balance sheet represents payments received by the Company in advance of the product being delivered.

 

Effective June 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products by applying the following steps: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to each performance obligation in the contract; and (5) recognizing revenue when each performance obligation is satisfied.

 

All revenue during the nine months ended December 31, 2021 was from product sales.

 

Cash and Cash Equivalents

 

All cash is maintained with a major financial institution in the United States. Deposits with this bank may occasionally exceed the amount of insurance provided on such deposits. For the purpose of the financial statements, cash includes cash in banks. Cash was $83 and $12,350 as of December 31, 2021 and March 31, 2021, respectively. There were no cash equivalents as of December 31, 2021 and March 31, 2021. The Federal Deposit Insurance Corporation (“FDIC”) insures these balances up to $250,000. At December 31, 2021 and March 31, 2021, cash in excess of the insured amount was $0.

 

Inventories

 

Inventories are stated at the lower of cost or net realizable value, using the first-in, first-out method. The Company reviews its inventory for obsolescence and any inventory identified as obsolete is reserved or written off. The Company’s determination of obsolescence is based on assumptions about the demand for its products, product expiration dates, estimated future sales, and management’s future plans.

 

Income Taxes

 

The Company accounts for income taxes under ASC 740 Income Taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized as of December 31, 2021 and March 31, 2021.

 

Commitments and Contingencies

 

The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. There are no known commitments or contingencies as of December 31, 2021 and March 31, 2021.

 

Recently Issued Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standard Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on the Company’s financial position or results of operations upon adoption.

 

There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on our consolidated financial position, results of operations or cash flows.

 

9

 

Note 3. Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. For the nine months ended December 31, 2021, the Company had net income of $218,993. As of December 31, 2021, the Company had net working capital of $292,497 and retained earnings of $163,575. The Company has begun to recognize revenue. Without additional capital, the Company may not be able to remain in business.

 

These factors raise a substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.

 

Achievement of the Rest EZ, Inc.’s business objective is basically dependent upon the judgment, skill and knowledge the Company’s management. Mr. Sosa is currently the Company’s sole executive officer and director. There can be no assurance that a suitable replacement could be found for our sole executive officer and director upon his retirement, resignation, inability to act on our behalf, or death.

 

Note 4. Deposits

 

The Company deposits funds with its supplier in advance of inventory purchases. The amount of outstanding deposits at December 31, 2021 and March 31, 2021 was $405,000 and $80,150, respectively.

 

Note 5. Inventory

 

Inventory consists of one product, a liquid gel capsule named Rest EZ Sleep Aid Supplement, manufactured by an unaffiliated outside provider. At December 31, 2021 and March 31, 2021, inventory consisted of the following:

 

   

December 31, 2021

   

March 31, 2021

 

Finished Goods Inventory

  $ 2,550     $ 26,450  

 

Note 6. Related Party Transactions

 

As of December 31, 2021 and March 31, 2021, Brandon Sosa, President and sole shareholder of the Company, had loaned the Company the amount of $115,136, net of repayments of $23,525, and $133,061, respectively, for operating capital. During the nine months ended December 31, 2021 and 2020, the Company charged to operations the amount of $7,615 and $7,981, respectively, as imputed interest on these loans.

 

During the nine months ended December 31, 2021, the Company’s founder and CEO sold 8,000,000 shares of common stock he personally owned to outside investors and contributed the proceeds in the amount of $80,000 to the Company. This amount is recorded as proceeds from contributed capital on the Company’s statement of changes in stockholder’s equity (deficit). See note 7.

 

Note 7. Stockholders Equity

 

During the nine months ended December 31, 2021, Brandon Sosa, the Company’s founder and CEO, sold 8,000,000 shares of common stock he personally owned to outside investors at a price of $0.01 per share. See note 6. Proceeds in the net amount of $80,000 were contributed to the Company, and are recorded as contributed capital on the Company’s statement of stockholder’s equity (deficit) at December 31, 2021. Previous to this sale of shares, Mr. Sosa owned 20,000,000 shares of the Company’s common stock; subsequent to this sale of shares, Mr. Sosa owned 12,000,000 shares of the Company’s common stock.

 

The Company has 100,000,000 authorized shares of common stock with $0.001 par value. As of December 31, 2021 and March 31, 2021, there were 20,000,000 shares of common stock outstanding.

 

On October 17, 2016, the Company issued 20,000,000 shares of common stock to Brandon Sosa, the Company’s President, in exchange for $20,000.

 

On May 26, 2021, the Company filed a Form S-1 with the Securities Exchange Commission in order to register the Company’s currently outstanding 20,000,000 shares of common stock. This registration statement became effective on July 19, 2021.

 

10

 

Note 8. Income Taxes

 

There is no current or deferred income tax expense or benefit for the period ended December 31, 2021.

 

The Company has not recognized an income tax expense or benefit for the period based on uncertainties concerning its ability to generate taxable income in future periods. The tax expense for the current period presented is offset by a valuation allowance (100%) established against deferred tax assets arising from operating losses and other temporary differences, the realization of which could not be considered more likely than not. In future periods, tax benefits and related deferred tax assets will be recognized when management considers realization of such amounts to be more likely than not.

 

Note 9. Subsequent Events

 

On January 15, 2022, the Company received a purchase order for 100,000 units of its Sleep Aid product in the amount of $900,000.

 

 

 

 

 

11

 

ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Forward Looking Statements

 

The following discussion should be read in conjunction with the consolidated financial statements and the related notes thereto, as well as all other related notes, and financial and operational references, appearing elsewhere in this document.

 

Certain information contained in this discussion and elsewhere in this report may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and is subject to the safe harbor created by that act. The safe harbor created by the Private Securities Litigation Reform Act will not apply to certain “forward looking statements” because we issued “penny stock” (as defined in Section 3(a)(51) of the Securities Exchange Act of 1934 and Rule 3(a)(51-1) under the Exchange Act) during the three year period preceding the date(s) on which those forward looking statements were first made, except to the extent otherwise specifically provided by rule, regulation or order of the Securities and Exchange Commission. We caution readers that certain important factors may affect our actual results and could cause such results to differ materially from any forward-looking statements which may be deemed to have been made in this Report or which are otherwise made by or on our behalf. For this purpose, any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “expect”, “believe”, “explore”, “consider”, “anticipate”, “intend”, “could”, “estimate”, “plan”, “propose” or “continue” or the negative variations of those words or comparable terminology are intended to identify forward-looking statements. Factors that may affect our results include, but are not limited to, the risks and uncertainties associated with:

 

Our ability to raise capital necessary to sustain our anticipated operations and implement our business plan,

 

 

Our ability to implement our business plan,

 

 

Our ability to generate sufficient cash to pay our lenders and other creditors,

 

 

Our ability to employ and retain qualified management and employees,

 

 

Our dependence on the efforts and abilities of our current employees and executive officers,

 

 

Changes in government regulations that are applicable to our current or anticipated business,

 

 

Changes in the demand for our services and different food trends,

 

 

The degree and nature of our competition,

 

 

The lack of diversification of our business plan,

 

 

The general volatility of the capital markets and the establishment of a market for our shares, and

 

 

Disruption in the economic and financial conditions primarily from the impact of past terrorist attacks in the United States, threats of future attacks, police and military activities overseas and other disruptive worldwide political and economic events, health pandemics and environmental weather conditions.

 

We are also subject to other risks detailed from time to time in our other filings with the SEC and elsewhere in this report. Any one or more of these uncertainties, risks and other influences could materially affect our results of operations and whether forward-looking statements made by us ultimately prove to be accurate. Our actual results, performance and achievements could differ materially from those expressed or implied in these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise.

 

12

 

Critical Accounting Policy and Estimates

 

Use of Estimates in the Preparation of Financial Statements

 

The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. These estimates include certain assumptions related to doubtful accounts receivable, stock-based services, valuation of financial instruments, operating right of use assets and liabilities, and income taxes. On an on-going basis, we evaluate these estimates, including those related to revenue recognition and concentration of credit risk. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Accounts subject to estimate and judgements are accounts receivable reserves, income taxes, intangible assets, contingent liabilities, and equity based instruments. Actual results may differ from these estimates under different assumptions or conditions. We believe our estimates have not been materially inaccurate in past years, and our assumptions are not likely to change in the foreseeable future.

 

Fair Value of Financial Instruments

 

The Company measures its financial assets and liabilities in accordance with accounting principles generally accepted in the United States of America. The estimated fair values approximate their carrying value because of the short-term maturity of these instruments or the stated interest rates are indicative of market interest rates. These fair values have historically varied due to the market price of the Company’s stock at the date of valuation.

 

Income Taxes

 

The Company uses the liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to financial statements carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. The measurement of deferred tax assets and liabilities is based on provisions of applicable tax law. The measurement of deferred tax assets is reduced, if necessary, by a valuation allowance based on the amount of tax benefits that, based on available evidence, is not expected to be realized.

 

Background

 

We were incorporated in the State of Wyoming on October 17, 2016, under the name of Amazing Ventures, Inc. Our articles of incorporation were amended on February 12, 2018 to change our name to Rest EZ, Inc.

 

Rest EZ, Inc. is in full production with product distribution to wholesalers and retailers as well as being available online at www.RestEz.net. Rest EZ Inc. has one sleep liquid gel capsule (named Rest EZ Sleep Aid Supplement).

 

General Introduction

 

Rest EZ, Inc. is currently in full production with full product distribution to wholesalers and retailers as well as online at www.RestEz.net. Rest EZ Inc. has commenced its major operations of having one product, a liquid gel capsule named Rest EZ Sleep Aid Supplement, manufactured by an unaffiliated outside provider (Sport Energy) that manufactures liquid gels to various companies, but has not distributed this product to anyone except Rest EZ, Inc. The Company is presently marketing the Rest EZ Sleep Aid Supplement to wholesalers, retailers, and online at www.RestEz.net. Rest EZ, Inc. is considered a Full Production and Full Distribution stage company because it has commenced all major operations with outside wholesalers and retailers, and has sold 77,694 bottles for $664,943 in total sales, with an retained earnings of $163,575 through December 31, 2021.

 

The product is a liquid gel capsule containing soybean oil, gelatin, valerian root, rosehips extract, purified water, yellow beeswax, L-Theanine, L-Threonine, lecithin, St. John’s Wort extract, lemon balm leaf extract, niacin and melatonin. The product is to be taken orally, preferably with water, at bedtime. Upon digestion the product is absorbed within the bloodstream ultimately providing the user an enhanced ability to sleep. One serving is two capsules per day. Intended customers are adults (persons over 18 years of age) who experience difficulty with sleeping.

 

13

 

Beyond the general FDA requirement that every dietary supplement be labeled as such, either with the term "dietary supplement" or with a term that substitutes a description of the product's dietary ingredient(s) for the word "dietary" (e.g., "herbal supplement" or "calcium supplement"), and the FDA’s safety monitoring responsibilities for dietary supplement firms once a dietary supplement is on the market, there are no additional FDA requirements specific to this product, and federal law does not require dietary supplements to be proven safe to FDA's satisfaction before they are marketed. Rest EZ, Inc. has not sent the product to the FDA for approval because it is not required, and because it would be a lengthy and costly process to have this product FDA approved when not required.

 

The liquid gel capsules are manufactured by Sport Energy, who adheres to very strict guidelines placed upon them by all agencies with whom they work. Sport Energy indicated they may use other outside sources to produce our product but has verbally indicated that all their ingredients used in any consumable products are very closely monitored. The manufacturer is registered as a Good Manufacturing Practices (GMP) company with NSF’s Dietary Supplement Certification program and the Natural Products Association (NPA), a status they have held for many years. Manufacturing of the capsules is complete, although manufacturing of the capsules will be ongoing as supply and demand dictates.

 

Rest EZ, Inc. has nothing proprietary about their product. At this time, Rest EZ, Inc. has no intellectual properties in connection with the capsules. However, we believe our product is superior to that of the competition due to the product being in a soft gel form, avoiding substantial product break down before digestion as happens with many competitors’ products.

 

The competition for and difficulty in selling a sleeping aid supplement product may affect our ability to maintain profitable operations in the future. Companies that are engaged in this product market include large, established companies with substantial capabilities and long earnings records.

 

The Company has minimal revenue. Without additional capital, the Company will not be able to remain in business. These factors raise a substantial doubt about the Company’s ability to continue as a going concern. Company financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern. Achievement of the Rest EZ, Inc.’s business objective is basically dependent upon the judgment, skill and knowledge the Company’s management. Mr. Sosa is currently the Company’s sole executive officer and director. There can be no assurance that a suitable replacement could be found for our sole executive officer and director upon his retirement, resignation, inability to act on our behalf, or death. Should the Company be unable to raise additional financing it would be unable to remain in business.

 

Business Development

 

The Company was incorporated on October 17, 2016. The Company has passed through all stages of development to full operations from incorporation, and the Company is currently in full production and distribution to wholesalers and retailers as well as online at www.RestEz.net.

 

Initial Sales Strategy

 

We have established a very strong sales approach; our approach utilizes direct sales through Mr. Sosa to our wholesalers and retailers as well as our company’s professional and easy to use web site. Our direct sales will be conducted by Mr. Sosa. He will market the product to wholesalers nationally, to retail chain stores and worldwide distributors. The Company’s current marketing strategy consists of various Point of Sale materials to include advertising posters, flyers and magnetic strips with the Company’s name and its product developed by Mr. Sosa in the past several months. In addition, sales will be done with referrals, distribution by our wholesalers and online marketing at www.RestEz.net

 

Description of Property

 

The Company uses a corporate office located at: 1398 W. Mason Hollow Drive, Riverton, Utah 84065. This facility is being provided to the Company free of charge by Mr. Sosa. Mr. Sosa is providing his own facility free of charge until the company needs additional space to store inventory over 100,000 bottles. Mr. Sosa indicates he has enough room to store 100,000 bottles of Rest EZ product, so no additional room is needed at this time, or in the near future. There are currently no proposed programs for renovations, improvements or developments of the facility currently in use.

 

14

 

Results of Operations

 

The Company is implementing its business plan and generated sales of $519,443, with cost of sales of $269,050 during the nine months ended December 31, 2021; there were no sales in the comparable period of the prior year. Selling, general and administrative costs were $23,785 and $12,580 for the nine months ended December 31, 2021 and 2020, respectively. Interest expense, which consisted of imputed interest on related party loans, was $7,615 and $7,981 for the nine months ended December 31, 2021 and 2020, respectively. This resulted in the company generating net income of $218,993 during the current period, compared to a net loss of $20,561 in the prior year.

 

The Company incurred general and administrative expenses of $9,875 and $12,520 and interest expense of $2,303 and $2,661 for the three months ended December 31, 2021 and 2020, respectively. The Company had net income of $167,822 for the three months ended December 31, 2021 compared to a net loss of $15,181 for the three months ended December 31, 2020.

 

Liquidity and Capital Resources

 

For the nine months ended December 31, 2021, cash used in operating activities was $92,267, compared to cash provided by operating activities of $92,500 for the nine months ended December 31, 2020. For the nine months ended December 31, 2021, cash provided by financing activities was $80,000, consisting of contributed capital from the sale of common stock. Cash provided by financing activities for the nine months ended December 31, 2020 was $0.

 

Plan of Operation

 

We have established a very strong sales approach; our approach utilizes direct sales through Mr. Sosa to our wholesalers and retailers as well as our company’s professional and easy to use web site. Our direct sales will be conducted by Mr. Sosa. He will market the product to wholesalers nationally, to retail chain stores and worldwide distributors. The Company’s current marketing strategy consists of various Point of Sale materials to include advertising posters, flyers and magnetic strips with the Company’s name and its product developed by Mr. Sosa in the past several months. In addition, sales will be done with referrals, distribution by our wholesalers and online marketing at www.restez.net

 

Over the next twelve months, Rest EZ, Inc. plans to build out its reputation further, and expand to additional wholesalers, retail chain stores, as well as expand sales to the public.

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues, or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

 

Inflation

 

In the opinion of management, inflation has not had a material effect on the Company’s financial condition or results of its operations.

 

Going Concern Considerations

 

The accompanying financial states have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company suffered a net loss from operations and has a net capital deficiency, which raises substantial doubt about its ability to continue as a going concern. Management’s plans regarding those matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Risk Factors

 

The Company’s business and success is subject to numerous risk factors as detailed in its Form S-1/A and other of its Current Reports on Form 8-K all of which reports are available at no cost at www.sec.gov.

 

15

 

ITEM 4. CONTROLS AND PROCEDURES

 

Our principal executive officer and principal financial officer are responsible for establishing and maintaining our disclosure controls and procedures. Such officers have concluded (based upon their evaluation of these controls and procedures as of the end of the period covered by this report) that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in this report is accumulated and communicated to management, including our principal executive and principal financial officer as appropriate, to allow timely decisions regarding required disclosure.

 

Our principal executive officer and principal financial officer have also indicated that, upon evaluation, there were no changes in our internal control over financial reporting or other factors during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. In addition, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Because of these inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

 

16

 

PART II OTHER INFORMATION

 

ITEM 1. Legal Proceedings

 

None.

 

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

ITEM 3. Defaults Upon Senior Securities

 

None.

 

ITEM 4. Mine Safety Disclosures

 

Not applicable.

 

ITEM 5. Other Information

 

None.

 

ITEM 6. Exhibits

 

Exhibit No.

 

Description

3.1*

 

Articles of Incorporation

3.2*

 

Amended Articles of Incorporation for Name Change to Rest EZ

3.3*

 

Amended Articles of Incorporation for Name Change to Rest EZ, Inc.

3.4*

 

Bylaws

 

 

 

31.1

 

Section 302 Certification

31.2

 

Section 302 Certification

32.1

 

Section 906 Certification

32.2

 

Section 906 Certification

 

 

 

101.INS

 

Inline XBRL Instance Document

101.SCH

 

Inline XBRL Taxonomy Extension Schema

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase

101.DEF

 

Inline XBRL Taxonomy Extension Definitions Linkbase

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase

 

 

 

104

 

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

* Previously filed with the Company's Form S-1 filed with the Securities and Exchange Commission on May 26, 2021.

 

17

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

Rest EZ, Inc.

 

 

Date: February 14, 2022

By: /s/ Brandon Sosa

 

Brandon Sosa

 

President, Chief Executive Officer (Principal Executive Officer)

 

 

 

 

 

Date: February 14, 2022

By: /s/ Brandon Sosa

 

Brandon Sosa

 

Chief Financial Officer (Principal Financial and Accounting Officer)

 

 

 

 

 

 

 

 

18
NONE false --03-31 Q3 2022 0001733861 0001733861 2021-04-01 2021-12-31 0001733861 2022-02-08 0001733861 2021-12-31 0001733861 2021-03-31 0001733861 2021-10-01 2021-12-31 0001733861 2020-10-01 2020-12-31 0001733861 2020-04-01 2020-12-31 0001733861 us-gaap:CommonStockMember 2020-09-30 0001733861 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001733861 us-gaap:RetainedEarningsMember 2020-09-30 0001733861 2020-09-30 0001733861 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001733861 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001733861 us-gaap:CommonStockMember 2020-12-31 0001733861 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001733861 us-gaap:RetainedEarningsMember 2020-12-31 0001733861 2020-12-31 0001733861 us-gaap:CommonStockMember 2021-09-30 0001733861 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001733861 us-gaap:RetainedEarningsMember 2021-09-30 0001733861 2021-09-30 0001733861 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001733861 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001733861 us-gaap:CommonStockMember 2021-12-31 0001733861 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001733861 us-gaap:RetainedEarningsMember 2021-12-31 0001733861 us-gaap:CommonStockMember 2020-03-31 0001733861 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001733861 us-gaap:RetainedEarningsMember 2020-03-31 0001733861 2020-03-31 0001733861 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-12-31 0001733861 us-gaap:RetainedEarningsMember 2020-04-01 2020-12-31 0001733861 us-gaap:CommonStockMember 2021-03-31 0001733861 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001733861 us-gaap:RetainedEarningsMember 2021-03-31 0001733861 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-12-31 0001733861 us-gaap:RetainedEarningsMember 2021-04-01 2021-12-31 0001733861 2020-04-01 2021-03-31 0001733861 2016-10-17 0001733861 srt:ChiefExecutiveOfficerMember 2021-12-31 0001733861 2016-10-17 2016-10-17 0001733861 us-gaap:SubsequentEventMember 2022-01-15 2022-01-15 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure